These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9370004)

  • 1. Pharmacology of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo-(F)-quinoxaline.
    Ikonomidou C; Turski L
    Ann N Y Acad Sci; 1997 Oct; 825():394-402. PubMed ID: 9370004
    [No Abstract]   [Full Text] [Related]  

  • 2. LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy.
    Potschka H; Löscher W; Wlaź P; Behl B; Hofmann HP; Treiber HJ; Szabo L
    Br J Pharmacol; 1998 Nov; 125(6):1258-66. PubMed ID: 9863655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the AMPA-receptor antagonist, NBQX, on neuron loss in dentate hilus of the hippocampal formation after 8, 10, or 12 min of cerebral ischemia in the rat.
    Hu P; Diemer NH; Bruhn T; Johansen FF
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):147-52. PubMed ID: 9040493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
    Shimizu-Sasamata M; Kawasaki-Yatsugi S; Okada M; Sakamoto S; Yatsugi S; Togami J; Hatanaka K; Ohmori J; Koshiya K; Usuda S; Murase K
    J Pharmacol Exp Ther; 1996 Jan; 276(1):84-92. PubMed ID: 8558460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excitotoxic effects of non-NMDA receptor agonists in organotypic corticostriatal slice cultures.
    Kristensen BW; Noraberg J; Jakobsen B; Gramsbergen JB; Ebert B; Zimmer J
    Brain Res; 1999 Sep; 841(1-2):143-59. PubMed ID: 10546997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline.
    Turski L; Jacobsen P; Honoré T; Stephens DN
    J Pharmacol Exp Ther; 1992 Feb; 260(2):742-7. PubMed ID: 1371159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Traumatic brain damage prevented by the non-N-methyl-D-aspartate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f] quinoxaline.
    Bernert H; Turski L
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5235-40. PubMed ID: 8643559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
    Desos P; Lepagnol JM; Morain P; Lestage P; Cordi AA
    J Med Chem; 1996 Jan; 39(1):197-206. PubMed ID: 8568808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticonvulsant activity of 5,7DCKA, NBQX, and felbamate against some chemoconvulsants in DBA/2 mice.
    De Sarro G; Ongini E; Bertorelli R; Aguglia U; De Sarro A
    Pharmacol Biochem Behav; 1996 Oct; 55(2):281-7. PubMed ID: 8951966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia.
    Gill R
    Cerebrovasc Brain Metab Rev; 1994; 6(3):225-56. PubMed ID: 7529037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620.
    De Vry J; Horváth E; Schreiber R
    Eur J Pharmacol; 2001 Oct; 428(2):203-14. PubMed ID: 11675037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX).
    Swedberg MD; Jacobsen P; Honoré T
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1113-21. PubMed ID: 7562477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection with NBQX in rat focal cerebral ischemia. Effects on ADC probability distribution functions and diffusion-perfusion relationships.
    Lo EH; Pierce AR; Mandeville JB; Rosen BR
    Stroke; 1997 Feb; 28(2):439-46; discussion 446-7. PubMed ID: 9040703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ability of NMDA and non-NMDA receptor antagonists to inhibit cerebral ischemic damage in aged rats.
    Suzuki Y; Takagi Y; Nakamura R; Hashimoto K; Umemura K
    Brain Res; 2003 Feb; 964(1):116-20. PubMed ID: 12573519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of AMPA receptor antagonists in models of stroke and neurodegeneration.
    Gressens P; Spedding M; Gigler G; Kertesz S; Villa P; Medja F; Williamson T; Kapus G; Levay G; Szenasi G; Barkoczy J; Harsing LG
    Eur J Pharmacol; 2005 Sep; 519(1-2):58-67. PubMed ID: 16112106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats.
    Takahashi M; Ni JW; Kawasaki-Yatsugi S; Toya T; Ichiki C; Yatsugi SI; Koshiya K; Shimizu-Sasamata M; Yamaguchi T
    J Pharmacol Exp Ther; 1998 Nov; 287(2):559-66. PubMed ID: 9808681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction.
    Xue D; Huang ZG; Barnes K; Lesiuk HJ; Smith KE; Buchan AM
    J Cereb Blood Flow Metab; 1994 Mar; 14(2):251-61. PubMed ID: 7509339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonist pharmacology of kainate- and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors.
    Wilding TJ; Huettner JE
    Mol Pharmacol; 1996 Mar; 49(3):540-6. PubMed ID: 8643094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma.
    Turski L; Huth A; Sheardown M; McDonald F; Neuhaus R; Schneider HH; Dirnagl U; Wiegand F; Jacobsen P; Ottow E
    Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10960-5. PubMed ID: 9724812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.